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Abstract
Synchronous composite tumors have been described but are uncommon. Moreover, simultaneous
occurrence of synchronous tumors in the same tissue or organ is even less common. We report
a case of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma and malignant
melanoma (MM) occurring synchronously in the same lymph node. Several cases of an association
between cutaneous malignancies and lymphoproliferative disorders have been reported. Some of
which included CLL and MM, occurring in the same patient often CLL after MM. The risk of having
CLL after MM has been reported to be increased. Various genetic and environmental etiologies
have been postulated, but have as yet not been proven. To our knowledge this is the first time that
synchronous occurrence of these two malignant processes in the same tissue is described. In this
case it is important that the melanoma was recognized in the excised lymph node, as this finding
had much more critical treatment and long term survival consequences.
Background
Synchronously diagnosed concomitant tumors are
uncommon, and occurrence of collision tumors is rare.
We report a case of chronic lymphocytic leukemia (CLL)/
small lymphocytic lymphoma (SLL) and malignant
melanoma (MM) occurring synchronously in the same
lymph node. CLL and MM occurring in the same patient,
often CLL after MM with a standardized incidence ratio of
2.3 [1]. Nevertheless, the relative risk of having CLL after
MM has been reported to be increased (standardized inci-
dence ratio of 2.3)[1] and the converse (i.e. melanoma)
after CLL also occurs with and estimated observed to
expected ratio of 2.79 [2].
Various genetic and environmental etiologies have been
postulated, but have as yet not been identified. To our
knowledge this is the first time that synchronously diag-
nosed collision tumor formed of CLL/SLL and MM is
described. In this case it is important that the melanoma
was recognized in the excised lymph node, as this finding
had much more critical treatment and long term survival
consequences.
Case presentation
A 58 year old man presented with a right axillary mass, of
4 months duration. He was otherwise relatively well and
asymptomatic. Past medical history was significant for
two previous excisions of cutaneous lesions, which were
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diagnosed as MM involving the left and right sides of the
back, nine years and two years ago respectively. The
patient has no history of receiving chemo or radiotherapy.
A physical examination performed at this time revealed a
right axillary mass with local tenderness measuring 10.0 ×
8.0 cm. The patient had been experiencing night sweats,
fevers and a twenty pound weight loss. The remainder of
the physical examination was significant for splenomeg-
aly, with the spleen tip palpated 7 cm. from the left lower
costal margin. No other lymphadenopathy or organome-
galy was detected.
Hematologic investigations
The peripheral blood showed a white blood cell count of
20.2 × 109 (reference range: 5–11 × 109). In addition, the
CBC revealed hemoglobin value of 12.6 g/dl (reference
range for men: 14.0–18.0 g/dl), and platelets was 203 ×
10-6/Liter (reference range: 150,000 to 450,000 platelets
per microliter) of blood. The peripheral smear showed
smudge cells.
As the patient presented with lymphadenopathy and
showed leukocytosis in the peripheral blood, flow cytom-
etry was performed on the patient's peripheral blood. This
showed a small population of monoclonal B cells with
Kappa light chain restriction, indicating a lymphoprolifer-
ative disorder. The cells were CD5 and CD23 positive and
CD38 and FMC7 negative. This phenotype is diagnostic of
CLL in the presence of the morphological features in the
peripheral blood smear.
Excision of the lymph node showed effacement of the
normal nodal architecture by a lymphoproliferative disor-
der composed of small cells (fig. 1), which on immuno-
histochemistry [table 1] were CD20, CD5 (fig. 2), bcl-2
(fig. 3), CD23 (fig. 4) positive, CD10 and cyclin D1 nega-
tive compatible with small lymphocytic lymphoma. Only
a single section showed a small metastatic focus of MM
(fig. 5), measuring 1.5 mm in maximum diameter. This
was of the epithelioid type that expressed MM markers,
(fig. 6, 7) consistent with the previous diagnosis.
Clinical outcome
The patient had a re-excision of the growing axillary mass.
He then had a new supraclavicular lymph node about one
month later as well as persistent edema of the right arm.
He received some radiation treatment at this time, after
which he appeared stable for about four months. The
patient then presented with shortness of breath and feel-
ing unwell, and CT scan showed multiple nodules in the
lung fields consistent with metastatic disease, at which
time chemotherapy was started.
Discussion
Synchronously diagnosed collision tumors are considered
a rare occurrence.
Cases presenting as multiple primary neoplasms may
occur concurrently as collision tumors or may be sepa-
rated temporally. It is important to realize that the con-
stellation of neoplasms may be more than coincidental
and may reflect underlying shared etiologic factors or may
be related to altered immunity [3], particularly given the
immunologic derangements that are known to occur with
CLL. Of course, underlying genetic susceptibilities may
also play important, although as yet not well delineated
roles.
In the current case, we report a composite MM and CLL
involving a single lymph node in a patient with MM diag-
noses known previously. However, his past medical his-
tory indicates absence of chemo or radiotherapy; that may
contribute to the present evolution of CLL. CLL and MM
have been reported previously as a metachronously diag-
nosed tumors in the English literature with MM usually a
subsequent cancer in patients with CLL [4]. CLL/SLL
Table 1: The panel of immunohistochemical reagents used
Antibody Clone Manufacturer Dilution
CD 20 L26 Dako (Carpinteria, CA) 1/1000
Bcl 2 124 Dako (Carpinteria, CA) 1/25
CD 5 4C7 Novocastra (Vision Biosystem, 
Norwell, MA)
1/50
CD 23 1B12 Novocastra (Vision Biosystem, 
Norwell, MA)
1/50
CD 10 56C6 Novocastra (Vision Biosystem, 
Norwell, MA)
1/25
Cyclin D1 SP4 MEDICORP/LAB VISION 
(Montreal, Quebec)
1/75
S 100 S100 Dako (Carpinteria, CA) 1/4000
Pan melanoma cocktail HMB45, MART-1, Tyrosinase BIOCARE MEDICAL (Concord, 
CA)
1/500
HMB 45 HMB 45 Dako (Carpinteria, CA) 1/200Diagnostic Pathology 2007, 2:34 http://www.diagnosticpathology.org/content/2/1/34
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developing after MM has also been reported. As far as we
know only two synchronously diagnosed cases of CLL and
MM have been reported previously in the English litera-
ture[5,3] [table 2], but none of these cases showed colli-
sion involvement of MM and CLL within the same site/
organ.
Synchronously diagnosed collision tumors of non Hodg-
kin's lymphomas (NHL) and MM have been reported
involving the same lymph node [5-7]. Such reports
include follicular, mantle and diffuse large cell lympho-
mas [5-7]. The current report adds to the list CLL and MM
which is to the best of our knowledge is the first report of
synchronously diagnosed CLL and MM involving the
same node at the same time.
The association of malignant melanoma with other malig-
nancies has been reported, including lymphoma, breast
cancer, leukemia[8] and renal cell carcinoma [9]. In addi-
tion, there is a known risk of risk of second malignant
neoplasms in CLL patients, including malignancies of the
lung, the brain and MM [2].
Restricted expression of CD23 within the lymphocytes in  chronic lymphocytic leukemia in contrast to malignant  melanoma cells, (CD23 200×) Figure 4
Restricted expression of CD23 within the lymphocytes in 
chronic lymphocytic leukemia in contrast to malignant 
melanoma cells, (CD23 200×).
Restricted expression of CD5 within the lymphocytes in  chronic lymphocytic leukemia in contrast to malignant  melanoma cells, (CD5 200×) Figure 2
Restricted expression of CD5 within the lymphocytes in 
chronic lymphocytic leukemia in contrast to malignant 
melanoma cells, (CD5 200×).
Lymph node involved with chronic lymphocytic leukemia  showing architectural effacement, (HE 40×) Figure 1
Lymph node involved with chronic lymphocytic leukemia 
showing architectural effacement, (HE 40×).
Restricted expression of Bcl-2 within the lymphocytes in  chronic lymphocytic leukemia in contrast to malignant  melanoma cells, (Bcl-2 200×) Figure 3
Restricted expression of Bcl-2 within the lymphocytes in 
chronic lymphocytic leukemia in contrast to malignant 
melanoma cells, (Bcl-2 200×).Diagnostic Pathology 2007, 2:34 http://www.diagnosticpathology.org/content/2/1/34
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Mature B cell neoplasms comprise ~4% of new cancers
each year around the world [10] and they account for over
90% of lymphoid neoplasms world wide [11]. About
6.7% of non Hodgkin lymphomas are classified as SLL/
CLL [11]. The majority of CLL patients are >50 years old
with a median age of 65 years [12].
The median age at diagnosis of MM is 53 years as MM is
now the commonest malignancy in Caucasians, between
25 and 29 years and in Caucasian men between 35–39
years [5]. The relative risk of subsequent MM for those
with CLL has been estimated to be between 2.79 and 3.1
[13,14].
Patients who have MM have been ascribed a future risk of
1.9 for developing CLL [2].
There is no identifiable common cytogenetic abnormality
or oncogene known between CLL and MM at this time.
Risk factors for developing malignant melanoma are
known to include ambient overexposure to sun light and
perhaps chemical exposure in some studies. With respect
to CLL, there are no proven studies to document sun light
overexposure or chemical as risk factors. However, UVB
present in sunlight has been suggested as a risk factor by
inducing immunosuppressive effects through deficient
antigen presentation and reduced T cell activity [15,16].
Composite tumors do raise the question of possible etio-
logical links and are of academic interest from this point
of view. More immediate questions include the impact of
composite tumors on management and prognosis.
Though CLL is eventually lethal, it usually takes a pro-
tracted and indolent course. The overall median survival
of CLL is 7 years [10]. On the other hand, MM stage II and
above presents a rather more significant survival threat.
Most then would consider that the primary target is to
manage the MM. Cytotoxic therapy, which is the mainstay
of systemic therapy for lymphoma[17], has a limited effi-
cacy in MM [5]. Although both MM and lymphoma are
radiosensitive[18] this raises issues of secondary unde-
sired consequences as radiation to areas of previous lym-
phadenectomy show a higher risk of subsequent
lymphedema (~20%)[5].
Expression of S100 within the nuclei and cytoplasm of the  malignant melanoma cells, (Melanoma cocktail 400×) Figure 7
Expression of S100 within the nuclei and cytoplasm of the 
malignant melanoma cells, (Melanoma cocktail 400×).
Simultaneous lymph node involvement by large epithelioid  melanoma cells and small monotonous lymphocytes of  chronic lymphocytic leukemia, (HE 200×) Figure 5
Simultaneous lymph node involvement by large epithelioid 
melanoma cells and small monotonous lymphocytes of 
chronic lymphocytic leukemia, (HE 200×).
Expression of Melanoma cocktail within the cytoplasmic  membranes of the malignant melanoma cells, (Melanoma  cocktail 400×) Figure 6
Expression of Melanoma cocktail within the cytoplasmic 
membranes of the malignant melanoma cells, (Melanoma 
cocktail 400×).Diagnostic Pathology 2007, 2:34 http://www.diagnosticpathology.org/content/2/1/34
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We present a collision tumor of CLL and MM, a report to
our knowledge has not been reported in the English liter-
ature. Through this case we reviewed the cases of synchro-
nous CLL and MM and expanded on the incidence,
demography, etiological correlation and management as
well as prognostic implications. In this case the impor-
tance of diagnosing the small amount of malignant
melanoma in the enlarged lymph node primarily occu-
pied by CLL/SLL was of critical importance in this patient
for decision making and treatment purposes, in addition
to having a significant adverse impact on overall survival.
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Table 2: Reported cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) and malignant melanoma (MM).
Cases 
reported
Age/Gender Risk factor Sites MM/CLL Breslow 
thickness
Clark's level Stage MM/
CLL
Interval between the 
diagnosis of the two 
tumors
Follow up/
duration
Schmid-
Wendtner 
MH et al, 
2002
46/F None Shoulder(MM
)/Axillary LN 
(CLL)
3 mm IV III/I Metachronous (MM 
presented first)
Not reported
Cahill RA et 
al, 2001
67/F Present* Lip (MM)/BM 
(CLL)
>3 mm V III/I Metachronous (CLL 
presented first)
Well/6 
months
Current case 68/M None Back(MM)/
Axillary LN 
(MM & CLL)
>3 mm III III/II Synchronous (MM & 
CLL on recurrence)
Well/2 years
* Farmer with history of exposure to ambient sunlight and carcinogenic chemicals.
• BM: Bone marrow, LN: Lymph node.